Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specia… Read more
Excelsior Biopharma (6496) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 0.004x
Based on the latest financial reports, Excelsior Biopharma (6496) has a cash flow conversion efficiency ratio of 0.004x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$3.80 Million) by net assets (NT$896.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Excelsior Biopharma - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Excelsior Biopharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Excelsior Biopharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Excelsior Biopharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GSE Systems Inc
NASDAQ:GVP
|
0.195x |
|
Yao I Fabric Co Ltd
TWO:4430
|
0.039x |
|
Kentucky First Federal Bancorp
NASDAQ:KFFB
|
-0.006x |
|
Secuve Co. Ltd
KQ:131090
|
0.022x |
|
Norsemont Mining Inc
PINK:NRRSF
|
-0.036x |
|
Korea Eng Cons
KO:023350
|
-0.205x |
|
HiTi Digital Inc
TW:3494
|
-0.084x |
|
Leclanche S.A. Reg.
LSE:0QP6
|
0.518x |
Annual Cash Flow Conversion Efficiency for Excelsior Biopharma (2017–2024)
The table below shows the annual cash flow conversion efficiency of Excelsior Biopharma from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$991.45 Million | NT$-99.80 Million | -0.101x | +17.50% |
| 2023-12-31 | NT$1.10 Billion | NT$-134.75 Million | -0.122x | -2785.29% |
| 2022-12-31 | NT$1.21 Billion | NT$5.49 Million | 0.005x | -89.99% |
| 2021-12-31 | NT$1.23 Billion | NT$55.82 Million | 0.045x | -88.82% |
| 2020-12-31 | NT$1.28 Billion | NT$520.81 Million | 0.406x | +400.08% |
| 2019-12-31 | NT$1.25 Billion | NT$-169.74 Million | -0.135x | -246.36% |
| 2018-12-31 | NT$1.37 Billion | NT$126.92 Million | 0.092x | -64.57% |
| 2017-12-31 | NT$1.34 Billion | NT$349.47 Million | 0.261x | -- |